Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 7,773 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo; placebo comparator condition Clear all
Completed Phase 3 Interventional Results available

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

NCT03679884
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

NCT04636229
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Amniotic Suspension Allograft, Placebo
Biological · Drug
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NCT01465802
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Dacomitinib, Doxycycline, Probiotic, Alclometasone cream
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
79
States / cities
Duarte, California • Fullerton, California • Irvine, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition Interventions for Cognitive Enhancement

NCT03841539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Mediterranean Diet, Study Supplement, Low-fat Diet
Behavioral · Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 16, 2026, 10:40 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801
View directory record Official record
Conditions
Crohn's Disease
Interventions
IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
87
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia

NCT00006400
View directory record Official record
Conditions
Hematologic Diseases, Anemia, Sickle Cell
Interventions
Hydroxyurea, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
9 Months to 18 Months
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

NCT00816907
View directory record Official record
Conditions
Schizophrenia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Palo Alto, California • Boca Raton, Florida • Iowa City, Iowa + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 16, 2026, 10:40 AM EDT
Recruiting Phase 2Phase 3 Interventional

Divided or Single Exposure (DOSE) Study

NCT05459402
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain, Methadone
Interventions
Methadone (100% dose), Methadone (50% dose)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 1 Interventional

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
EOS789, Placebo, Renvela
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Botox in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder

NCT01350375
View directory record Official record
Conditions
Forward Head Posture With Associated Episodic Headache Disorder
Interventions
Botox, Saline
Drug
Lead sponsor
The Research Center of Southern California
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

DORA and LP in Alzheimer's Disease Biomarkers

NCT06274528
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lemborexant 10 mg, Lemborexant 20mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Biology of Resilience

NCT01011465
View directory record Official record
Conditions
Oxytocin, Placebo
Interventions
intranasal oxytocin, Placebo, Social support, No Social Support
Drug · Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
22 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Oct 16, 2026, 10:40 AM EDT
Not listed Phase 2 Interventional

MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease

NCT05194163
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MW150, Placebo
Drug
Lead sponsor
Neurokine Therapeutics
Industry
Eligibility
50 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

NCT02596893
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
150
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Recruiting Phase 3 Interventional

Treatment of Chronic Thyroid Eye Disease With MHB018A

NCT07622121
View directory record Official record
Conditions
Thyroid Eye Disease, TED
Interventions
MHB018A injection, MHB018A injection Placebo
Drug
Lead sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830
View directory record Official record
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 10:40 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

NCT03982199
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Diseases
Interventions
RSV Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
5,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
40
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD

NCT00532493
View directory record Official record
Conditions
PTSD, Sleep Disorders
Interventions
prazosin, placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
15
States / cities
Loma Linda, California • Long Beach, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

NCT01260584
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Metformin for the Prevention of the Metabolic Side-effects of Zyprexa

NCT00682448
View directory record Official record
Conditions
Metabolic Complications
Interventions
Metformin, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 2 Interventional

Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

NCT03717272
View directory record Official record
Conditions
Marijuana Abuse
Interventions
AEF0117, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
21 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 16, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 16, 2026, 10:40 AM EDT